INBRAIN Neuroelectronics Announces Collaboration to Advance Graphene-based Brain-computer Interfaces
INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, announced it has entered into a know-how collaboration agreement with Mayo Clinic. The collaboration seeks to accelerate the development and commercialization of INBRAIN’s precision BCI-Tx for patients with unmet needs in neurological-related disorders.
As part of the collaboration, INBRAIN and Mayo Clinic experts will work together on a non-exclusive know-how exchange to engage in hands-on evaluation of INBRAIN’s investigational BCI-Tx platform in IRB-approved settings with the goal of accelerating, high-quality evidence generation.
“Our goal is to translate the unique performance of graphene and AI to deliver benefits for patients and clinicians,” said Carolina Aguilar, CEO and Co-Founder, INBRAIN Neuroelectronics. “With Mayo Clinic’s clinical know-how, alongside other leading U.S. and European centers, we seek to validate our platform in real-world workflows, accelerate evidence generation, and move responsibly toward patient-focused BCI therapeutics.”
INBRAIN is also announcing the formation of a U.S. subsidiary to collaborate with leading U.S. academic centers, with locations set to open in Boston and the West Coast, while maintaining its global headquarters and R&D in Barcelona, Spain. The initial Boston office will serve as a hub for U.S.-based clinical trials and build the foundation for commercialization and therapeutic expansion of its BCI-Tx beyond Parkinson’s disease. INBRAIN is also advancing scalable manufacturing processes for its graphene-based BCI to enable broader clinical and commercial adoption worldwide.
INBRAIN has raised $124 million in financing to date from a global syndicate of medtech and deeptech investors, including Aliath Bioventures, Asabys Partners, CDTI, Catalan Government (Avançsa & ICF), FondICO, Graybella Capital, IMECXpand, Mayo Clinic, the European Innovation Council, Truventuro and Vsquared Ventures.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
Read the original article on Business Wire.